Thermo Fisher Scientific Rallies Near Highs on Resilient End Markets

Thermo Fisher Scientific Inc. shares recently reached a 52-week high, closing at $721.63 on November 9, 2026. The stock gained 24.5% over the past year, with investors paying higher valuation multiples as the price-to-earnings ratio expanded from 32.4 to 37.5. For the twelve months ended September 2026, the company's net income increased 7.6% compared to the prior year.

The advance follows third-quarter operating momentum across several key segments. On its fiscal third-quarter call, management noted that revenue in the Laboratory Products and Biopharma Services division grew 15%, led by strength in pharma services and clinical research. Company filings for the quarter ended September 26 showed total revenue increased 9.1% to $12.14 billion from $11.12 billion a year prior, while net income rose to $1.72 billion with diluted earnings per share of $4.64. In an investor letter, Liontrust GF Global Dividend Fund reported that analytical instruments were bolstered by demand for electron microscopes from semiconductor customers tied to AI infrastructure investments.

Broader sector trends also provided tailwinds as customer inventory destocking stabilized. Market commentary pointed to recovering early-stage biotech funding and consistent spending from pharmaceutical clients. Organic revenue grew 6% in the third quarter, with industrial markets gaining from electron microscopy demand, although academic and government channel revenues remained flat. In addition, the bioproduction franchise within Life Sciences Solutions registered 1% organic growth with adjusted operating margins reaching 37.6%.

Technical researchers observed mixed short-term indicators around the recent peak. JournalArta reported that the November 9 close of $721.63 placed the stock above its 20-day moving average of $690.13 and broke through its upper Bollinger band of $717.92. However, trading volume was slightly lower than the 20-day average. Several market analysts maintain positive expectations, carrying an average price target of $744.11 over the past month, while others caution that the company's $41.4 billion debt load, potential timing shifts in pharma-services revenue, and stretched valuation multiples could present risks.